Rosetta Genomics, Isis to Co-develop microRNA-based Drugs for Liver Cancer | GenomeWeb

NEW YORK, Feb. 22 (GenomeWeb News) - Isis Pharmaceuticals and Rosetta Genomics plan to co-discover and -develop antisense drugs that regulate microRNAs for the treatment of hepatocellular carcinoma, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.